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Background: Reliable population-based data on the prevalence and characteristics of
primary headache across the lifespan are essential. However, robust data are lacking.
Methods: We utilized questionnaire data from a random general population sample
in Germany, that comprised 2,478 participants aged ≥14 years. A standardized
questionnaire addressing headache and headache treatment was filled in during the
face-to-face survey.
Results: The 6-month prevalence of self-reported headache in the total sample
amounted to 39.0% (known diagnosis of migraine 7.2%; tension-type headache 12.4%;
another diagnosis or unknown diagnosis 23.4%). Age-specific prevalence rates were
37.9% (14–34 years), 44.6% (35–54 years), 38.5% (55–74 years), and 26.9% (≥75
years). Compared to age group 14–34, participants aged 35–54 were more (OR = 1.29,
95%-CI 1.05–1.60, p = 0.018) and those aged ≥75 were less (OR = 0.55, 95%-CI
0.40–0.76, p < 0.001) likely to have any headache. Of the participants with headache,
79.5% reported headache on <4 days per month, 15.6% on 4–14 days per month and
4.9% on >14 days per month. The frequency of headache did not differ significantly
between age groups in men [χ2(3, N = 384) = 1.45, p> 0.05], but in women [χ
2
(3, N = 651) =
21.57, p< 0.001]: women aged≥75 years were over-represented in the group reporting
4–14 headache days per month. The analgesic use (days per month) differed significantly
between age groups among participants with headache on <4 days per month and on
>14 days per month: 1.8 (14–34 years), 2.5 (35–54 years), 3.2 (55–74 years), and 3.4
(≥75 years), respectively 7.9 (14–34 years), 11.4 (35–54 years), 18.4 (55–74 years), and
22.8 (≥75 years).
Conclusions: In general, the prevalence of headache decreases with age. However,
older women suffer from more frequent attacks and older participants take analgesics
Müller et al. Headache Across the Lifespan
on more days per month than younger participants. This might put them at risk of
medication overuse which may lead to medication overuse headache. More research
is needed to understand these specifics in headache frequency and treatment behavior
in older people.
Keywords: migraine, tension-type headache, lifespan, population-based study, 6-month prevalence, headache
attacks, headache impact, use of analgesics
INTRODUCTION
Headache is the most frequent neurological disorder worldwide
(1). According to estimates, the 1-year prevalence is around 38%
for tension-type headache (TTH), and 10% for migraine (2, 3).
These two types of headache account for 13% of all disability-
adjusted life-years (DALYs) caused by neurological disorders
(1). For purposes of healthcare planning, reliable population-
based data on the characteristics of headache across the lifespan,
such as prevalence, frequency of attacks and headache impact,
are essential. Additional data on behavioral patterns across the
lifespan in people with headache, such as physician consultation
and use of medication, are also important. There are hardly any
robust research results available.
Previous findings in prevalence refer almost exclusively to
children and adolescents as well as young and middle-aged
adults (4). Prevalence studies including older persons suffer from
different limitations. First, a number of studies date back at least
two decades (5–8). Second, some studies do not differentiate
between different age groups among elderly people (6, 8–11).
Third, many study samples make it difficult to generalize the
findings to the whole population because they exclude either
rural (12, 13) or urban residents (14–16). Age-specific patterns
of attack frequency, medical use and headache impact have rarely
been studied.
The aim of the present analysis is to (a) describe the 6-
month prevalence of self-reported headache across the lifespan
in general and (b) to identify age-specific characteristics of
frequency of headache, headache impact and frequency of




The analysis is based on data from a random general
population sample in Germany with participants aged 14–94
years. A cross-sectional questionnaire survey was performed
through face-to-face contacts conducted by an independent
demographic consulting company (USUMA, Berlin, Germany).
The sociodemographic data was collected using a standardized
face-to-face interview. For the collection of headache-related data
we used standardized questionnaires filled in by the participants
themselves. For sample selection, random multi-stage sampling
procedures were employed. First, 258 regional sample points
Abbreviations: ICHD, International Classification of Headache Disorders; MOH,
medication overuse headache; TTH, tension-type headache.
in Germany were determined (stage 1). Subsequently, 19
households per sample point were selected using the random-
route procedure (stage 2) (17). Members of households, who
met the inclusion criteria (age above 14, able to read, and
understand German) were randomly selected using the Kish-
selection-grid technique (stage 3) (18). The sample was designed
to be representative in terms of age, sex, household size, and
population by federal state. In total, 4,838 subjects were selected
for the study, of whom 52% participated (N = 2,510). Reasons
for non-participation were refusal to take part (n = 1,453), three
unsuccessful attempts to contact the household member (n =
863), and illness of the selected subjects or his/her incapacity
to follow the interview (n = 8). The final sample consisted
of 2,510 interviewed participants. From the current analysis
32 subjects were excluded [reasons for exclusion were missing
answers to following questions: (a) occurrence of headache in
the last 6 months n = 5; (b) headache diagnosis n = 13; (c)
headache frequency n = 15]. Thus, n = 2,478 interviewees were
entered into the present analysis. A comparison of included
subjects vs. drop-outs revealed no differences regarding sex
composition, χ2(1, N = 2,510) = 1.09, p = 0.373 and mean age,
U = 35947.50; p = 0.364, r = 0.02. An adjustment factor
was calculated on the basis of the German population structure
regarding age, sex, household size, and population by federal
state. German population parameters were provided by data
from the 2016 Microcensus conducted by the German Federal
Statistical Office. Based on the adjustment factor a weighted
random sample was created, the structure of which corresponds
to that of the German population (19). Data collection took place
from September to November 2016. All participants gave their
written informed consent. The Ethics Committee of the Faculty
of Medicine, University of Leipzig, reviewed and approved the
study (297/16-ek).
Questionnaire
The standardized questionnaire about headache and headache
treatment consisted of 36 items. The introductory screening
question was “Did you have a headache in the last 6 months?”
The advantage over lifetime prevalence is that data depicting
headache in a maximum of the last 12 months show a higher
reliability due to a lower recall bias, particularly among older
subjects (4). The headache frequencies were assessed using
a five-point ordinal scale: (1) <1 day per month; (2) 1–
3 days per month; (3) 4–14 days per month; (4) >14 days
per month, but not daily; (5) daily. For statistical analysis
we summarized the five categories into three classes: <4 days
per month, 4–14 days per month, >14 days per month. In
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those participants having indicated the presence of headache,
data regarding headache types was assessed by self-reporting
using an item allowing multiple answers. The question used
here was: “Do you know the diagnosis of your headache?”
Response options were “migraine,” “TTH,” “cluster headache,”
“other headache,” and “unclear headache (unknown diagnosis).”
We summarized the headache types “cluster headache,” “other
headache,” and “unclear headache (unknown diagnosis)” to the
category “other headache.” As a reliable distinction between
migraine with and without aura cannot be made solely by
such a questionnaire, it was not assessed in our study (4).
The impact of headache on daily life was assessed using the
German version of the Headache Impact Test (HIT-6) (20).
The HIT-6 is a six-item, self-administered questionnaire with
three items assessing the impact of headache during the past
4 weeks and three items without a specific timeframe. Five
response categories were given: “never,” “rarely,” “sometimes,”
“very often,” and “always.” The total score can range from 36
to 78. Higher scores indicate a greater impact of headache
on the ability to function on the job, at school, at home and
in social situations. The HIT-6 provides a grading indicating
four levels of headache impact: little or no impact (<50),
some impact (50–55), substantial impact (56–59), and severe
impact (≥60). To determine lifetime physician consultation
for headache, participants were asked if they ever consulted a
physician (ormore than one) because of their headaches (yes/no).
Analgesic use was assessed with the question: “How many days
per month do you use analgesics on average?” Additionally, we
used a standardized sociodemographic questionnaire to assess
following parameters: age, sex, school education, and living alone
(yes/no). Data regarding the community size was taken from the
sampling plan.
Statistical Analysis
The data of the weighted random sample were analyzed using
descriptive statistics. The 6-month prevalence of self-reported
headache was estimated with 95% confidence interval (CI). To
test for differences between sociodemographic characteristics and
sex, we used Fisher‘s exact test, Welch’s t-test and Pearson’s chi-
squared test. To identify the factors associated with headache, we
conducted a multivariate binary logistic regression that included
sex and age group. We conducted ANOVAs to assess the effects
of sex and age group on frequency of headache, analgesic use and
headache impact (21). Differences were considered significant
if the two-tailed p-value was p < 0.05. To analyze categorical
variables we calculated adjusted Pearson residuals (22).We tested
these residuals in the cells using a Bonferroni correction. For
6-month prevalence of headache, scatterplot smoothing LOESS
curves were fitted to both men and women, with non-linear




The sociodemographic characteristics of the weighted sample
stratified for sex are presented in Table 1. The age of the
participants ranged from 14 to 94 years.
6-Month Prevalence of Self-Reported
Headache in Men and Women Across the
Lifespan
In our sample, the weighted 6-month prevalence of self-reported
headache amounted to 39.0%. 7.2% indicated to have received
a diagnosis of migraine, 12.4% a diagnosis of TTH, and 23.4%
had another diagnosis or had not received a diagnosis. 50.7% of
the participants reporting headache had consulted a physician
because of their headache, women (54.1%) more often than men
(45.3%), χ2(1, N = 950) = 6.9, p= 0.009.
Logistic regression analysis was employed to predict the
probability of having headache in the last 6 months. Predictor
variables were sex and age group (14–34 years, 35–54 years, 55–
74 years, ≥75 years). The overall significance of the model was
χ
2
(4, N = 2478) = 3194.99, p < 0.001 (Likelihood-Ratio-Test). The
analysis revealed both predictors remaining significant in the
equation: sex (reference men) (OR = 2.22, 95%-CI 1.88–2.62, p
< 0.001) and age groups (reference 14–34 years): 35–54 years
(OR = 1.29, 95%-CI 1.05–1.60, p = 0.018), 55–74 years (OR =
0.97, 95%-CI 0.78–1.21, p = 0.800), ≥75 years (OR = 0.55, 95%-
CI 0.40–0.76, p < 0.001). The odds ratio for sex indicated that
women were 2.2 times more likely to have a headache than men.
The age group variable was dummy coded using age group 14–34
years as the reference group. Participants aged 35–54 years were
1.29 times more likely to have a headache than participants aged
14–34 years. The odds of headache in age group 14–34 years were
1.82 times higher than for participants aged ≥75 years (inverted
odds ratio for age group ≥75 years).
Univariate analyses indicated that the weighted prevalence
of headache was higher in women compared to men in all
headache categories: all headache types (male-to-female ratio
1:1.6), χ2(1, N = 2,477) = 85.6, p < 0.001; migraine (male-to-
female ratio 1:2.7), χ2(1, N = 2,477) = 42.1, p < 0.001; TTH (male-
to-female ratio 1:2), χ2(1, N = 2,477) = 42.1, p < 0.001; other
headaches (male-to-female ratio 1:1.3), χ2(1, N = 2,477) = 15.2, p
< 0.001. Prevalence rates of reported headache were 37.9% (14–
34 years), 44.6% (35–54 years), 38.5% (55–74 years), and 26.9%
(≥75 years). Participants aged 35–54 years were over-represented
among headache participants (adjusted residual: 4.0), while
participants aged≥75 years less likely to have headache (adjusted
residual: −4.4). In Figure 1, weighted age-specific 6-month
prevalences are depicted, represented by scatterplot smoothing
LOESS curves for men and women. Up to the age of around 45
years, the prevalence rose with age. After that age, prevalence
declined with a steeper slope starting around 65 years (for more
information see Supplement Table 1).
Frequency of Headache in Men and
Women Across the Lifespan
Of the participants with headache, 79.5% reported headache on
<4 days per month, 15.6% on 4–14 days per month and 4.9%
on >14 days per month. We conducted a non-parametric two-
way ANOVA to assess the effects of sex and age groups on
the frequency of headache. The frequency of headache differed
significantly for sex, χ2(1, N = 1,035) = 20.73, p < 0.001, and age
groups, χ2(3, N = 1,035) = 7.20, p < 0.05. We found a significantly
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TABLE 1 | Sociodemographic characteristics of the study sample according to sex.
Variable Total sample Men Women p-Value
n = 2,477 n = 1,215 n = 1,262
Age, mean (SD) 48.71 (19.15) 47.47 (18.91) 49.90 (19.31) 0.002a
Age group, n (%) 14–24 years 319 (12.9) 166 (13.7) 153 (12.1) 0.059b
25–34 years 359 (14.5) 196 (16.1) 163 (12.9)
35–44 years 360 (14.4) 172 (14.2) 188 (14.9)
45–54 years 449 (18.1) 225 (18.5) 224 (17.7)
55–64 years 388 (15.7) 191 (15.7) 197 (15.6)
65–74 years 327 (13.2) 143 (11.8) 184 (14.6)
75 years or older 275 (11.1) 122 (10.0) 153 (12.1)
High school graduation (yes), n (%) 520 (21.1) 283 (23.3) 237 (18.9) 0.008c
Marital status, n (%) Unmarried 721 (29.2) 407 (33.6) 314 (25.0) <0.001b
Married 1,266 (51.3) 641 (52.4) 625 (51.0)
Divorced 258 (10.5) 119 (9.8) 139 (11.1)
Widowed 223 (9.0) 44 (3.6) 179 (14.2)
Living with partner (yes), n (%) 1,501 (61.1) 759 (63.1) 742 (59.1) 0.047c
Living in a city (yes), n (%) 1,378 (55.7) 690 (56.8) 688 (54.6) 0.275c
Community size, n (%) <5,000 residents 101 (4.1) 48 (4.0) 53 (4.2) 0.468b
5,000–19,999 residents 227 (9.2) 119 (9.8) 108 (8.6)
20,000–99,999 residents 430 (17.4) 199 (16.4) 231 (18.3)




cFisher‘s exact test; SD, standard deviation.
interaction between sex and age groups, χ2(3, N = 1,035) = 13.92,
p < 0.05. This interaction was due to the fact that women
were under-represented among those with headache on <4 days
per month (adjusted residual: −2.7). Given the hybrid type of
interaction we conducted two separate non-parametric one-way
ANOVAs for men and women. The frequency of headache did
not differ significantly for age groups in men, χ2(3, N = 384) = 1.45,
p > 0.05, but in women, χ2(3, N = 651) = 21.57, p < 0.001 (see
Figure 2A). Women aged 35–54 years (adjusted residual: 3.0)
were more likely and women aged ≥75 years (adjusted residual:
−4.0) were less likely to have headache on <4 days per month.
Additionally, women aged≥75 years (adjusted residual: 3.1) were
observed significantly more than expected among those with
headache on 4–14 days per month. Detailed information on the
frequency of headache regarding age group and sex is provided
in the Supplement Table 1.
Headache Impact in Men and Women
Across the Lifespan
41.6% of the participants with headache reported no or little
headache impact, 25.1% some impact, 12.2% substantial impact
and 21.1% severe impact (HIT-6). We conducted a parametric
two-way ANOVA to assess the effects of sex and age groups on the
total score of HIT-6. The headache impact differed significantly
for sex, F(1; 1,005) = 36.34, p < 0.001. Women (mean: 52.78, SD:
8.66) reported a stronger impact than men (mean: 49.24, SD:
8.08). Age groups did not differ significantly, F(3; 1,005) = 1.30, p
= 0.274.Mean values for headache impact for the four age groups
14–34 years, 35–54 years, 55–74 years,≥75 years were 51.29 (SD:
8.72), 51.52 (SD: 8.08), 51.14 (SD: 8.90), and 53.32 (SD: 10.51).
There was no significant interaction effect between sex and age
groups, F(3; 1,005) = 0.98, p= 0.402.
Frequency of Analgesic Use in Men and
Women Across the Lifespan
Of the participants with headache, 43.3% reported taking
analgesics on <2 days per month, 50.8% on 2–10 days per
month and 5.9% on more than 10 days per month. A non-
parametric two-way ANOVA was employed to assess the effects
of sex and age groups on the frequency of analgesic use. The
frequency of analgesic use differed statistically significant for sex,
χ
2
(1, N = 999) = 30.80, p < 0.001 and age groups χ
2
(1, N = 999) =
9.52, p = 0.025. There was no significantly interaction between
sex and age groups to the frequency of analgesic use, χ2(3, N = 999)
= 2.50, p > 0.05 (see Figure 2B). The significant association
between sex and analgesic use was due to the smaller numbers
of women (adjusted residual: −5.6) within those with <2 days
per month and the increased numbers of women (adjusted
residual: 4.6) among those with analgesic use on 2–10 days
per month and >10 days per month (adjusted residual: 2.1).
The significant association between age groups and analgesic
use was attributable to the higher than expected number of
participants aged ≥75 years (adjusted residual: 4.0) among those
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FIGURE 1 | Weighted age-specific 6-month prevalence of self-reported
headache, represented by scatterplot smoothing LOESS curves for men and
women.
with analgesic use on>10 days per month (for more information
see the Supplement Table 1).
Frequency of Analgesic Use in Men and
Women Across the Lifespan Depending on
the Frequency of Headache
In the following, we tested whether there is a association between
age group and analgesic use, respectively sex and analgesic use
even if the participants belong to the same headache frequency
category. We conducted parametric two-way ANOVAs for this
purpose to assess the effects of sex and age groups on analgesic
use (number of days per month) in three different headache
frequency categories: <4 days per month, 4–14 days per month,
and >14 days per month.
In the headache frequency category “<4 days per month,”
the analgesic use differed statistically significant for age groups
F(3; 788) = 4.40, p= 0.004. The age group means showed a linear
trend (p= 0.006). According to the Tukey-HSD, age group 14–34
years, mean: 1.75 (SD: 2.28), differed significantly from age group
55–74 years, mean: 3.22 (SD: 5.10) (−1.47, p = 0.002). Sex did
not differ significantly, F(1; 788) = 2.44, p = 0.119. There was no
significant interaction effect between sex and age groups, F(3; 788)
= 0.35, p= 0.790.
In the headache frequency category “4–14 days per month,”
the analgesic use differed neither in age groups, F(3; 153) = 1.08,
p = 0.361, nor in sex, F(1; 153) = 1.30, p = 0.256. There was
no significantly interaction effect between sex and age groups,
F(3; 153) = 0.36, p= 0.790.
In the headache frequency category “>14 days per month,”
the analgesic use differed statistically significant for age groups,
F(3; 43) = 4.09, p = 0.012. The age group means showed a linear
trend (p= 0.003). According to the Tukey-HSD, age group 14–34
years, mean: 7.89 (SD: 6.96), differed significantly from age group
≥75 years, mean: 22.83 (SD: 11.84) (−14.94, p = 0.014). Sex did
not differ significantly, F(1; 43) = 1.77, p = 0.191. There was no
significant interaction effect between sex and age groups, F(2; 43)
= 0.78, p= 0.465 (see Figure 3).
DISCUSSION
We analyzed the 6-month prevalence and characteristics of
self-reported headache across the lifespan in a random general
population sample in Germany aged 14–94 years.
In our study, the overall headache prevalence in the past
6 months in Germany, as obtained with a questionnaire, was
39%. This frequency is slightly lower than the mean prevalence
in Europe (53%) reported by Stovner and Andree (4). They
evaluated 49 studies with different timeframes of headache
prevalence (a third of them contained lifetime prevalence data)
and different methods of data collection (nearly a third of studies
with a timeframe for headache ≤1 year were based on personal
interviews). Both, lifetime prevalence of headache (compared to
a timeframe for headache≤1 year) and prevalence rates based on
personal interviews (compared to questionnaires) result in higher
figures. The prevalence rate in our German study is comparable
to Norway (38%) (23), Estonia (41%) (24), and Italy (43%) (12).
Furthermore, we found a 6-month prevalence of self-reported
diagnosed migraine of 7.2% with a male-to-female ratio of 1:2.7.
The mean prevalence of migraine in Europe is two times higher
(14.7%) with a quite similar male-to-female ratio of 1:2.2 (14.7%)
(4). The difference is most likely due to half of the men and
women with migraine in Germany not knowing their headache
diagnosis. This result supports findings of other studies (25, 26).
The 6-month prevalence of self-reported diagnosed TTH in our
study (12.4%) is approximately five times lower than the mean
prevalence in Europe (62.6%) (4). The male-to female ratio in
TTH of our sample (1:2) differs only slightly from that in other
European studies (1:1.3). The proportions of women and men
with TTH who do not know their diagnosis are similarly high.
It is estimated that people with headache underreport TTHmore
often than migraine due to the lesser severity of symptoms and
impact of TTH (27–30). 23.4% of all participants had another
diagnosis or did not know their diagnosis, which corresponds
to 60% of all those suffering from headache. This result is at
glance surprising, as maximally 8–10% of all headache patients
suffer from secondary headaches only, and just about 1–2% of
the headache patients suffer from primary headaches other than
migraine or TTH (31–36). Our conclusion is that about 35%
of the population in Germany has primary headaches and that
about 44% of the patients with primary headache are not aware
of their specific diagnosis. This fits well with the result that
49% of the participants with headache had not seen a physician
because of their headache (and consequently not received a
diagnosis). However, diagnosing or classifying the individual
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FIGURE 2 | Headache frequency (A) and analgesic use (B) depending on age group.
headache allows for an appropriate treatment and management
(37–41). The low consultation rate probably reflects the general
opinion that headaches cannot be treated specifically, or that
self-medication is sufficient.
We found that the headache prevalence was associated with
sex and age group. Higher headache prevalence in women is well-
documented in the literature (4, 16, 42, 43). Compared to the
age group 14–34 years, participants aged 35–54 years are more
and those aged ≥75 are less likely to have headache (inverted u-
shape, see Figure 1). This likely reflects the known age-specific
prevalence rates of migraine and TTH. Migraine reaches a peak
during the fourth decade of life and remains constant during the
fifth decade, TTH peaks between the ages of 30 and 39 years
(44, 45). The lowest prevalence of TTH and migraine is at age
70 years and older (13, 42, 44, 46, 47).
Of the participants with headache, 80% reported headache
on <4 days per month. Lipton et al. (29) reported a very
similar proportion (79%) for participants with migraine in an
American sample. Although in clinical practice, in addition
to attack frequency, other criteria (e.g., duration of attack,
impairment of quality of life) are considered when deciding
on preventive treatment, we assume from an epidemiological
perspective that about 80% of all participants with headache
do not need preventive therapy (48). In our sample, of the
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FIGURE 3 | Frequency of analgesic use (days a month) depending on
frequency of headache and age group.
participants with headache, 5% reported chronic headache (>14
days per month), which is about 2% of our total sample. Stovner
et al. (49) estimated, based on data from 8 European countries,
that about 4% of the adult population in Europe suffers from
chronic headache. Data from Germany were not included. Our
data suggest that the proportion among the population aged≥14
in Germany is lower.
In the following we discuss the three most important results of
our study:
First, we could show that in women, but not in men, the
frequency of headache attacks differs between age groups.
Women in old age (≥75 years) tend to have more headache
days (per month) than younger women. This tendency is
known for migraine patients (15, 50). However, it has not
yet been analyzed in the literature whether this trend applies
to both men and women. It is possible that the association
between age and frequency of migraine attacks exists only in
women. The cause of higher attack frequency in older patients
is not known. It could be hypothesized that only patients with
primarily severe migraine still have it in older age and that
more patients with less severe migraine become headache-free
in older age. In this case, the higher headache frequency in old
age would be the result of a selection effect. Furthermore, the
polypharmacy in older patients may exacerbate a pre-existing
headache or trigger medication overuse headache (MOH),
e.g., regular intake of analgesics for chronic arthritis pain
(46, 51, 52).
Second, the impact of headache did not differ between age
groups. We found no other study in which the impact of
headache was analyzed across the lifespan. Given that among
women the frequency of attacks increases with age, the finding
of a stable headache impact appears paradoxical. Plausible
would have been an increase in headache impact with age. We
suppose that psychological adaptation processes, according to
the theory of Rothermund and Brandstädter (53) about coping
with deficits and losses in later life, play an important role in
the subjective perception of the headache impact. It is possible
that, based on the longer duration of the disease, headache
sufferers in old age are better able to cope with their condition
than younger ones. Theymay bemore efficient able to generate
affectively relieving cognitions.
Third, we could show that among participants with a headache
frequency of >14 days per month those aged ≥75 years use
analgesics on more days per month than younger participants.
The reason is unclear. In our study, we used a categorical
variable to measure headache frequency. We do not have data
about the actual number of headache days per month. It is
possible that older people with >14 headache days per month
have a higher frequency of headache than younger people.
In this case, the higher headache frequency could result in a
higher burden of disease, which is compensated by a more
frequent intake of analgesics. It is also conceivable, however,
that older people with the same headache frequency as
younger people may take more analgesics than younger ones.
However, it could also be due to the intake of analgesics for
treatment of concomitant (non-headache) painful conditions,
which are more frequent with increasing age. Furthermore,
the more frequent intake of analgesics can also be the reason
for higher blood pressure in elderly persons (54). Studies
indicate that roughly half of the individuals with headache
on >14 days per month use analgesics daily or almost daily
(55, 56). Our data suggest that the risk may be higher
in old age.
Physicians should pay attention to the frequency of headache
attacks and medication use in older people. The more
frequent intake of analgesics might put older people at risk
of developing medication overuse and subsequently MOH
(57). Especially for older women who consult a physician for
non-headache pain, taking the history should also include
questions about self-medication to treat headache. General
practitioners play a key role, as they are often consulted by
older patients. They should be aware of the possibility of MOH
and refer the patients to a specialist if necessary. Based on
the assumption that the higher analgesic use of older subjects
was mainly caused by headache, our data implies an unmet
need of pharmacological management of headache in the
elderly. Pharmacological headache trials should therefore not
be limited to the age of 65, but should include also individuals
aged 70–75 years or even older.
LIMITATIONS
An important limitation is the fact that our headache type
classification was based on participants’ self-reports of prior
headache diagnoses, necessarily underestimating migraine and
TTH prevalence. It is possible that the category “other” includes
many undiagnosed migraine and TTH patients. In this regard,
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our results on prevalence rates are less accurate than studies
that reported prevalence based on ICHD III beta criteria.
Furthermore, we cannot say whether the attacks and more
frequent use of analgesics in old age are due to migraine or TTH,
nor whether they are due to primary or secondary headache.
We assume that the response to the question about the use
of analgesics was influenced by an anchoring effect (58): the
headache-related questions were preceded by an introductory
sentence (“The following questions deal with headaches. Please
answer as accurately as you can.”); the question about analgesic
use was asked in the latter part of the headache-related
questionnaire and followed immediately after three questions
related directly to the treatment of headache. Nevertheless,
we cannot rule out the possibility that the analgesics may
have been taken because of other painful, not headache-related
symptoms. Especially for chronic headache, strong associations
to musculoskeletal symptoms and to fibromyalgia have been
reported (59, 60). It is still unclear whether these relationships
are moderated by age.
CONCLUSION
In our representative German sample of participants aged ≥14
years and living in private households, about 39% suffer from
headache, and many participants with headache do not know
their diagnosis. We estimate this proportion at about 44%, based
on the proportions of participants reporting migraine and TTH
diagnoses compared to the known prevalences of these disorders.
Headache prevalence peaks in the age group 35–54 years, the
lowest prevalence was found in the age group 75 years and
more. Women in old age have more headache days per month
than younger women. Among participants with a headache
frequency of >14 days per month, those aged ≥75 years use
analgesics on more days per month than younger participants,
putting them at risk for MOH. More research is needed to
understand these specifics of headache in old age. As a first
step toward an effective treatment of primary headaches in the
general population, it also seems necessary to encourage people
suffering from headache to contact a physician and receive a
headache diagnosis.
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